Panitumumab after Progression on Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients: a Single Institution Experience
…, P Fedele, M D'Amico, MC Chetrì… - Tumori …, 2015 - journals.sagepub.com
Aims and background Few data describe the activity of panitumumab after cetuximab-irinotecan-based
regimen failure in patients with KRAS wild-type metastatic colorectal cancer (WT …
regimen failure in patients with KRAS wild-type metastatic colorectal cancer (WT …
Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units
…, S Miraglia, F Oniga, R Biason, MC Chetrì… - Anticancer …, 2008 - ar.iiarjournals.org
Background: Palliative chemotherapy significantly reduces mortality in patients with stage IV
colon cancer, but is less prescribed with rising age. In this paper, we highlight the pattern of …
colon cancer, but is less prescribed with rising age. In this paper, we highlight the pattern of …
Panitumumab after progression on cetuximab in patients with KRAS wild-TYPE (WT) metastatic colorectal cancer (MCRC): A single institution experience.
…, P Schiavone, P Fedele, M D'Amico, MC Chetrì… - 2013 - ascopubs.org
e14605 Background: Cetuximab and panitumumab are monoclonal antibodies that target
EGFR, approved for the treatment of KRAS WT MCRC. Few data describe the activity of …
EGFR, approved for the treatment of KRAS WT MCRC. Few data describe the activity of …
Chemotherapy induced-hair loss: A digni-life with DigniCap—Our experience and patient's satisfaction.
…, P Fedele, A Marino, N Calvani, M D'amico, MC Chetrì… - 2017 - ascopubs.org
e12016 Background: Alopecia (A) is one of the most emotionally distressing side effects of
chemotherapy (CT). CT-induced A may lead to a negative body image, contributing to worsen …
chemotherapy (CT). CT-induced A may lead to a negative body image, contributing to worsen …
The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a …
J Giuliani, M Indelli, M Marzola, E Raisi… - Tumori …, 2012 - journals.sagepub.com
Aims and background Skin rash is a predictable and manageable side effect of anti-EGFR
therapy such as cetuximab. The aim of this study is to estimate the costs for the foreseeable …
therapy such as cetuximab. The aim of this study is to estimate the costs for the foreseeable …
Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer
G Rosati, S Cordio - Tumori Journal, 2006 - journals.sagepub.com
Aims and background Irinotecan is a standard option for relapsed/refractory advanced colorectal
cancer. Although in a recently reported, randomized trial it was found that a regimen of …
cancer. Although in a recently reported, randomized trial it was found that a regimen of …
Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma
Objective: To evaluate clinical and demographic characteristics and the results of cytotoxic
treatments of KRAS G12C , KRAS other , and next-generation sequencing (NGS) panel …
treatments of KRAS G12C , KRAS other , and next-generation sequencing (NGS) panel …
Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer
PF Zhang, D Xie, Q Li - Tumori Journal, 2020 - journals.sagepub.com
Objective: To evaluate the cost-effectiveness of addition of fruquintinib to best supportive care
(BSC) in third-line treatment for patients with metastatic colorectal cancer (CRC). Methods: …
(BSC) in third-line treatment for patients with metastatic colorectal cancer (CRC). Methods: …
Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice
M Pistelli, M Scartozzi, A Bittoni, E Galizia… - Tumori …, 2011 - journals.sagepub.com
Aims and background Soon after the approval of irinotecan for second-line therapy of advanced
gastric cancer, the FOLFIRI regimen represented a possible treatment choice in clinical …
gastric cancer, the FOLFIRI regimen represented a possible treatment choice in clinical …
Fixed-dose-rate gemcitabine infusion in patients with advanced pancreatic or biliary tree adenocarcinoma
JM Mané, A Sancho, A Muñoz, I Rubio… - Tumori …, 2010 - journals.sagepub.com
Aims and background Gemcitabine is an effective agent in pancreatic adenocarcinoma.
Fixed-dose-rate gemcitabine has an interesting biological and clinical rationale, with successful …
Fixed-dose-rate gemcitabine has an interesting biological and clinical rationale, with successful …